<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Deferasirox</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01609</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the <span class="caps">USA</span> for this purpose.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01609/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01609/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01609.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01609.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01609.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01609.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01609.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01609">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Deferasiroxum</td><td>Latin</td><td>INN</td></tr><tr><td>ICL 670</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Exjade</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/iron-chelating-agents">Iron Chelating Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>201530-41-8</td></tr><tr><th>Weight</th><td>Average: 373.3615<br>Monoisotopic: 373.106255983</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BOFQWVMAQOTZIW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Triazoles</td></tr><tr><th>Direct parent</th><td>Phenyltriazoles</td></tr><tr><th>Alternative parents</th><td>Aminobenzoic Acid Derivatives; Benzoic Acids; Benzoyl Derivatives; Phenols and Derivatives; Polyols; Carboxylic Acids; Enols; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>benzoic acid; benzoic acid or derivative; benzoyl; phenol derivative; benzene; polyol; enolate; polyamine; enol; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenyltriazoles. These are organic aromatic compounds containing a phenyl group sustituted with a triazole ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.</td></tr><tr><th>Pharmacodynamics</th><td>Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.</td></tr><tr><th>Mechanism of action</th><td>Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>14.37 &#177; 2.69 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Deferasirox is highly (~99%) protein bound almost exclusively to serum albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.</p></td></tr><tr><th>Route of elimination</th><td>Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces.
Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).</td></tr><tr><th>Half life</th><td>The mean elimination half-life ranged from 8 to 16 hours following oral administration.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.993</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8508</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5089</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7808</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.894</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8431</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8708</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7212</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8686</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6466</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5802</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7105</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8221</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8179</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5717</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6607
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8519
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9524
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1119 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9684
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9072
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.novartis.com">Novartis AG</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, for suspension</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Possible physicochemical interaction</td></tr><tr><td><a href="/drugs/DB00006">Bivalirudin</a></td><td>Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy. 
</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.</li>
<li>Food causes inconsistent increases in the bioavailability of this product.</li>
<li>Tablets should be completely dispersed in water, orange juice or apple juice and the resulting suspension should be ingested immediately (after swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed).</li>
<li>Tablets should be taken on an empty stomach at least 30 minutes before a meal, preferably at the same time everyday.</li></ul></td></tr></tbody></table>